Hillhouse Capital Management Ltd. maintained its stake in Mirati Therapeutics, Inc. (NASDAQ:MRTX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 725,000 shares of the biotechnology company’s stock at the end of the second quarter. Hillhouse Capital Management Ltd. owned approximately 2.90% of Mirati Therapeutics worth $2,646,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in MRTX. Broadfin Capital LLC grew its position in Mirati Therapeutics by 153.1% in the 1st quarter. Broadfin Capital LLC now owns 2,090,801 shares of the biotechnology company’s stock valued at $10,872,000 after buying an additional 1,264,800 shares in the last quarter. Aviva Holdings Ltd. grew its position in Mirati Therapeutics by 44.6% in the 1st quarter. Aviva Holdings Ltd. now owns 2,880,702 shares of the biotechnology company’s stock valued at $14,980,000 after buying an additional 888,617 shares in the last quarter. Boxer Capital LLC grew its position in Mirati Therapeutics by 37.0% in the 1st quarter. Boxer Capital LLC now owns 1,037,994 shares of the biotechnology company’s stock valued at $5,398,000 after buying an additional 280,059 shares in the last quarter. Renaissance Technologies LLC bought a new position in Mirati Therapeutics in the 1st quarter valued at about $854,000. Finally, Sabby Management LLC grew its position in Mirati Therapeutics by 150.4% in the 1st quarter. Sabby Management LLC now owns 249,735 shares of the biotechnology company’s stock valued at $1,299,000 after buying an additional 150,000 shares in the last quarter. Hedge funds and other institutional investors own 60.17% of the company’s stock.

Mirati Therapeutics, Inc. (NASDAQ:MRTX) traded down 4.181% during trading on Thursday, hitting $14.325. 374,149 shares of the stock traded hands. The firm’s 50-day moving average is $7.65 and its 200 day moving average is $5.03. The stock’s market cap is $357.68 million. Mirati Therapeutics, Inc. has a 52 week low of $2.70 and a 52 week high of $15.40.

COPYRIGHT VIOLATION WARNING: “Mirati Therapeutics, Inc. (MRTX) Position Held by Hillhouse Capital Management Ltd.” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/10/05/mirati-therapeutics-inc-mrtx-position-held-by-hillhouse-capital-management-ltd.html.

A number of equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. SunTrust Banks, Inc. reiterated a “buy” rating and issued a $13.00 target price on shares of Mirati Therapeutics in a research report on Monday. CIBC assumed coverage on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. They issued an “outperform” rating and a $18.00 target price for the company. Citigroup Inc. reiterated a “buy” rating and issued a $16.00 target price (up previously from $8.00) on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. Finally, Cann assumed coverage on shares of Mirati Therapeutics in a research report on Tuesday, September 19th. They issued an “outperform” rating for the company. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $12.63.

Mirati Therapeutics Profile

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Stock Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related stocks with our FREE daily email newsletter.